Omnicell (OMCL) Reports Q2 EPS of $0.17, Beats by a Penny
More News related to OMCL
- Omnicell Boosts Pharmacy Efficiency with Enhanced WorkflowRx(TM) Central Pharmacy Automation Software
- Omnicell Improves Nursing Workflow with New Anywhere RN(TM) Remote Medication Management Application
- Auriga Reiterates a 'Buy' on Omnicell (OMCL), Raises Price Target & Estimates
- Randall A. Lipps, Chairman, President and CEO of Omnicell, Inc., Selected to Join UCSF School of Nursing Board of Overseers
- Notable Analyst Rating Changes 5/1: RIMM, IRM, OMCL Upgraded; SQNM, GIGM, KEX Downgraded
Omnicell, Inc. (Nasdaq: OMCL) reports Q2 EPS of $0.17, 1 cent better than the analyst estimate of $0.16. Revenues for the quarter were $63.4 million, versus the consensus of $62.01 million.
Omnicell, Inc. provides medication control and patient safety solutions for acute care health facilities.
Related Categories
EarningsStocks Mentioned
-0.46Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
